MX2019010206A - Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). - Google Patents
Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).Info
- Publication number
- MX2019010206A MX2019010206A MX2019010206A MX2019010206A MX2019010206A MX 2019010206 A MX2019010206 A MX 2019010206A MX 2019010206 A MX2019010206 A MX 2019010206A MX 2019010206 A MX2019010206 A MX 2019010206A MX 2019010206 A MX2019010206 A MX 2019010206A
- Authority
- MX
- Mexico
- Prior art keywords
- tigit
- binding
- tigit antibodies
- antigen
- antibody
- Prior art date
Links
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000049823 human TIGIT Human genes 0.000 abstract 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464529P | 2017-02-28 | 2017-02-28 | |
| US201862616779P | 2018-01-12 | 2018-01-12 | |
| PCT/US2018/020239 WO2018160704A1 (en) | 2017-02-28 | 2018-02-28 | Anti-tigit antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010206A true MX2019010206A (es) | 2019-12-11 |
Family
ID=63370305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010206A MX2019010206A (es) | 2017-02-28 | 2018-02-28 | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). |
| MX2023006212A MX2023006212A (es) | 2017-02-28 | 2019-08-27 | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006212A MX2023006212A (es) | 2017-02-28 | 2019-08-27 | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200040082A1 (enExample) |
| EP (1) | EP3589313A4 (enExample) |
| JP (3) | JP2020510422A (enExample) |
| KR (1) | KR20190123749A (enExample) |
| CN (1) | CN111050788A (enExample) |
| AU (2) | AU2018227489B2 (enExample) |
| BR (1) | BR112019017550A2 (enExample) |
| CA (1) | CA3053486A1 (enExample) |
| IL (1) | IL268517A (enExample) |
| MA (1) | MA47694A (enExample) |
| MX (2) | MX2019010206A (enExample) |
| SG (2) | SG11201907278VA (enExample) |
| WO (1) | WO2018160704A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2279412B1 (en) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| CN109689694B (zh) | 2016-05-19 | 2022-11-22 | 通用医疗公司 | 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台 |
| WO2018102536A1 (en) | 2016-11-30 | 2018-06-07 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| CA3113301A1 (en) | 2018-09-11 | 2020-03-19 | iTeos Belgium SA | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2020206169A1 (en) | 2019-04-02 | 2020-10-08 | Kupper Thomas S | Methods for identifying progression of a primary melanoma |
| MX2021013850A (es) * | 2019-06-13 | 2022-01-07 | Green Cross Corp | Anticuerpo contra tigit y uso del mismo. |
| AU2020298324A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
| MX2022004086A (es) * | 2019-11-05 | 2022-07-12 | Merck Patent Gmbh | Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos. |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN112409450B (zh) * | 2020-03-29 | 2023-01-24 | 郑州大学 | TIGIT-IgV的亲和剂及其应用 |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| JP2023525082A (ja) | 2020-05-07 | 2023-06-14 | アンスティテュ・クリー | 免疫抑制線維芽細胞集団のバイオマーカーとしてのａｎｔｘｒ１及び免疫療法に対する応答を予測するためのその使用 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| WO2021258337A1 (en) * | 2020-06-24 | 2021-12-30 | Huahui Health Ltd. | Human monoclonal antibodies against tigit for immune related diseases |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CN116157418A (zh) * | 2020-08-05 | 2023-05-23 | 晶体生物科学股份有限公司 | 抗tigit抗体及其使用方法 |
| WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| US20240141436A1 (en) | 2021-02-17 | 2024-05-02 | iTeos Belgium SA | Compounds, Compositions and Methods of Treatment Thereof |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| US20240182571A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| EP4377350A2 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| US20250179176A1 (en) | 2022-05-02 | 2025-06-05 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| AU2023284422A1 (en) | 2022-06-07 | 2024-12-19 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| CN119907811A (zh) | 2022-08-02 | 2025-04-29 | Ose免疫疗法公司 | 针对cd28的多功能分子 |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY183503A (en) * | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| US20150132744A1 (en) * | 2013-11-13 | 2015-05-14 | Oregon Health And Science University | Methods of detecting cells latently infected with hiv |
| CA2971732A1 (en) * | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US10766957B2 (en) * | 2015-08-14 | 2020-09-08 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
| SMT202500003T1 (it) * | 2015-09-25 | 2025-03-12 | Hoffmann La Roche | Anticorpi anti-tigit e procedimenti di utilizzo |
-
2018
- 2018-02-28 MX MX2019010206A patent/MX2019010206A/es unknown
- 2018-02-28 BR BR112019017550A patent/BR112019017550A2/pt not_active Application Discontinuation
- 2018-02-28 MA MA047694A patent/MA47694A/fr unknown
- 2018-02-28 AU AU2018227489A patent/AU2018227489B2/en not_active Ceased
- 2018-02-28 SG SG11201907278VA patent/SG11201907278VA/en unknown
- 2018-02-28 KR KR1020197027438A patent/KR20190123749A/ko active Pending
- 2018-02-28 JP JP2019546327A patent/JP2020510422A/ja not_active Withdrawn
- 2018-02-28 WO PCT/US2018/020239 patent/WO2018160704A1/en not_active Ceased
- 2018-02-28 EP EP18760515.9A patent/EP3589313A4/en not_active Withdrawn
- 2018-02-28 SG SG10202103227YA patent/SG10202103227YA/en unknown
- 2018-02-28 CA CA3053486A patent/CA3053486A1/en active Pending
- 2018-02-28 CN CN201880027323.6A patent/CN111050788A/zh active Pending
-
2019
- 2019-08-05 IL IL268517A patent/IL268517A/en unknown
- 2019-08-15 US US16/541,575 patent/US20200040082A1/en not_active Abandoned
- 2019-08-27 MX MX2023006212A patent/MX2023006212A/es unknown
-
2020
- 2020-10-28 US US17/082,586 patent/US20210269527A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/853,134 patent/US20230134375A1/en not_active Abandoned
- 2022-07-26 JP JP2022118823A patent/JP2022141910A/ja active Pending
-
2024
- 2024-01-10 AU AU2024200157A patent/AU2024200157A1/en not_active Abandoned
- 2024-02-26 JP JP2024026609A patent/JP2024057038A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210269527A1 (en) | 2021-09-02 |
| US20200040082A1 (en) | 2020-02-06 |
| US20230134375A1 (en) | 2023-05-04 |
| AU2024200157A1 (en) | 2024-01-25 |
| KR20190123749A (ko) | 2019-11-01 |
| EP3589313A4 (en) | 2021-05-19 |
| IL268517A (en) | 2019-09-26 |
| AU2018227489A1 (en) | 2019-08-22 |
| CA3053486A1 (en) | 2018-09-07 |
| MA47694A (fr) | 2021-05-19 |
| AU2018227489B2 (en) | 2023-10-19 |
| SG10202103227YA (en) | 2021-04-29 |
| WO2018160704A1 (en) | 2018-09-07 |
| JP2020510422A (ja) | 2020-04-09 |
| CN111050788A (zh) | 2020-04-21 |
| BR112019017550A2 (pt) | 2020-04-14 |
| JP2022141910A (ja) | 2022-09-29 |
| EP3589313A1 (en) | 2020-01-08 |
| JP2024057038A (ja) | 2024-04-23 |
| WO2018160704A9 (en) | 2019-10-17 |
| SG11201907278VA (en) | 2019-09-27 |
| MX2023006212A (es) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006212A (es) | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). | |
| MX2021002002A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit). | |
| MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| PH12020550408A1 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
| PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
| MX2021001711A (es) | Proteínas biespecíficas modificadas. | |
| EA202092847A1 (ru) | Антитела к cd3 и их применение | |
| NZ602176A (en) | Cd37-binding molecules and immunoconjugates thereof | |
| PH12018500635A1 (en) | Bispecific antibodies specific for pd1 and tim3 | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| CR20110577A (es) | Proteínas de unión a il-1 | |
| MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| NZ743379A (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
| JOP20180117B1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
| TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| NZ759835A (en) | Cd38 modulating antibody | |
| MY189618A (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| EA201990673A1 (ru) | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты | |
| MY210065A (en) | Humanized antibody molecules to cd138 and uses thereof |